Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Cemdisiran by Alnylam Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData,...
Data Insights
Cemdisiran by Alnylam Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...